---
title: 'Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in
  Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11'
date: '2023-08-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37527011/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20230802180705&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSIONS: Utomilumab-mediated 4-1BB agonism combined with axi-cel
  therapy had a manageable safety profile. Dual 4-1BB and CD28 costimulation is a
  feasible therapeutic approach that may enhance CAR T-cell expansion in patients
  with ...'
disable_comments: true
---
CONCLUSIONS: Utomilumab-mediated 4-1BB agonism combined with axi-cel therapy had a manageable safety profile. Dual 4-1BB and CD28 costimulation is a feasible therapeutic approach that may enhance CAR T-cell expansion in patients with ...